Antide supplier GnRH antagonist for cancer research

Abarelix acetate | CAS# 785804-17-3 | GnRHR Antagonist

Related CAS #

No information provided.

Synonym

Abarelix acetate

IUPAC/Chemical Name

N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparaginyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-D-alaninamide, acetate salt

InChi Key

ZRHCGBCCWJPSQF-JOOIWXSYSA-N

InChi Code

InChI=1S/C72H95ClN14O14.C2H4O2/c1-41(2)32-54(64(93)80-53(17-10-11-30-77-42(3)4)72(101)87-31-13-18-60(87)69(98)78-43(5)63(75)92)81-68(97)58(38-62(74)91)84-70(99)61(37-46-22-27-52(90)28-23-46)86(7)71(100)59(40-88)85-67(96)57(36-48-14-12-29-76-39-48)83-66(95)56(34-45-20-25-51(73)26-21-45)82-65(94)55(79-44(6)89)35-47-19-24-49-15-8-9-16-50(49)33-47;1-2(3)4/h8-9,12,14-16,19-29,33,39,41-43,53-61,77,88,90H,10-11,13,17-18,30-32,34-38,40H2,1-7H3,(H2,74,91)(H2,75,92)(H,78,98)(H,79,89)(H,80,93)(H,81,97)(H,82,94)(H,83,95)(H,84,99)(H,85,96);1H3,(H,3,4)/t43-,53+,54+,55-,56-,57-,58-,59+,60+,61+;/m1./s1

SMILES Code

CC(N[C@H](CC1=CC(C=CC=C2)=C2C=C1)C(N[C@H](CC3=CC=C(Cl)C=C3)C(N[C@H](CC4=CC=CN=C4)C(N[C@@H](CO)C(N(C)[C@@H](CC5=CC=C(O)C=C5)C(N[C@H](CC(N)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CCCCNC(C)C)C(N6CCC[C@H]6C(N[C@H](C)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O.OC(C)=O

Appearance

A crystalline solid

Purity

>95% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

λmax: 226 nm

• Debruyne F, Bhat G, Garnick MB. Abarelix for injectable suspension: first-in- class gonadotropin-releasing hormone antagonist for prostate cancer. Future Oncol. 2006 Dec;2(6):677-96. doi: 10.2217/14796694.2.6.677. PMID: 17155895.
• Hogle WP. Abarelix (plenaxis). Clin J Oncol Nurs. 2004 Dec;8(6):663-5. doi: 10.1188/04.CJON.663-669. PMID: 15637961.
• Abarelix: abarelix-depot-F, abarelix-depot-M, abarelix-L, PPI 149, R 3827. Drugs R D. 2003;4(3):161-6. doi: 10.2165/00126839-200304030-00004. PMID: 12757402.
• Kirby RS, Fitzpatrick JM, Clarke N. Abarelix and other gonadotrophin- releasing hormone antagonists in prostate cancer. BJU Int. 2009 Dec;104(11):1580-4. doi: 10.1111/j.1464-410X.2009.08924.x. PMID: 20053189.
• Mongiat-Artus P, Teillac P. Abarelix: the first gonadotrophin-releasing hormone antagonist for the treatment of prostate cancer. Expert Opin Pharmacother. 2004 Oct;5(10):2171-9. doi: 10.1517/14656566.5.10.2171. PMID: 15461552.
• Reddy GK. Abarelix (Plenaxis): a gonadotropin-releasing hormone antagonist for medical castration in patients with advanced prostate cancer. Clin Prostate Cancer. 2004 Mar;2(4):209-11. doi: 10.1016/s1540-0352(11)70046-4. PMID: 15072602.
• Doehn C, Jocham D. Technology evaluation: Abarelix, Praecis pharmaceuticals. Curr Opin Mol Ther. 2000 Oct;2(5):579-85. PMID: 11249760.
• Retraction statement: Reconstitution of Plenaxis® (Abarelix) 100 mg for injection is more effective with a vortex-like mixer than when performed manually. J Pharm Pract. 2010 Feb;23(1):78. doi: 10.1177/0897158253577919. PMID: 21507797.
• Beer TM, Ryan C, Bhat G, Garnick M; Abarelix Study Group. Dose-escalated abarelix in androgen-independent prostate cancer: a phase I study. Anticancer Drugs. 2006 Oct;17(9):1075-9. doi: 10.1097/01.cad.0000231476.84782.55. PMID: 17001181.
• Abarelix (Plenaxis) for advanced prostate cancer. Med Lett Drugs Ther. 2004 Mar 15;46(1178):22-3. PMID: 15037857.
• Tomera K, Gleason D, Gittelman M, Moseley W, Zinner N, Murdoch M, Menon M, Campion M, Garnick MB. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J Urol. 2001 May;165(5):1585-9. PMID: 11342922.
• Wong SL, Lau DT, Baughman SA, Menchaca D, Garnick MB. Pharmacokinetics and pharmacodynamics of abarelix, a gonadotropin-releasing hormone antagonist, after subcutaneous continuous infusion in patients with prostate cancer. Clin Pharmacol Ther. 2003 Apr;73(4):304-11. doi: 10.1016/s0009-9236(02)17637-5. PMID: 12709720.
• Koch M, Steidle C, Brosman S, Centeno A, Gaylis F, Campion M, Garnick MB; Abarelix Study Group. An open-label study of abarelix in men with symptomatic prostate cancer at risk of treatment with LHRH agonists. Urology. 2003 Nov;62(5):877-82. doi: 10.1016/s0090-4295(03)00656-3. PMID: 14624912.
• Garnick MB, Mottet N. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist. BJU Int. 2012 Aug;110(4):499-504. doi: 10.1111/j.1464-410X.2011.10708.x. Epub 2011 Nov 16. PMID: 22093775.
• Wong SL, Lau DT, Baughman SA, Fotheringham N, Menchaca D, Garnick MB. Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75. J Clin Pharmacol. 2004 May;44(5):495-502. doi: 10.1177/0091270004264920. PMID: 15102870.
• McLeod D, Zinner N, Tomera K, Gleason D, Fotheringham N, Campion M, Garnick MB; Abarelix Study Group. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology. 2001 Nov;58(5):756-61. doi: 10.1016/s0090-4295(01)01342-5. PMID: 11711355.
• Beer TM, Garzotto M, Eilers KM, Lemmon D. Phase II study of abarelix depot for androgen independent prostate cancer progression during gonadotropin- releasing hormone agonist therapy. J Urol. 2003 May;169(5):1738-41. doi: 10.1097/01.ju.0000059584.47272.9d. PMID: 12686821.
• Beer TM, Garzotto M, Eilers KM, Lemmon D, Wersinger EM. Targeting FSH in androgen-independent prostate cancer: abarelix for prostate cancer progressing after orchiectomy. Urology. 2004 Feb;63(2):342-7. doi: 10.1016/j.urology.2003.09.045. PMID: 14972486.
• Garnick MB, Campion M. Abarelix Depot, a GnRH antagonist, v LHRH superagonists in prostate cancer: differential effects on follicle-stimulating hormone. Abarelix Depot study group. Mol Urol. 2000 Fall;4(3):275-7. PMID: 11062384.
• Trachtenberg J, Gittleman M, Steidle C, Barzell W, Friedel W, Pessis D, Fotheringham N, Campion M, Garnick MB; Abarelix Study Group. A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol. 2002 Apr;167(4):1670-4. doi: 10.1097/00005392-200204000-00021. PMID: 11912385.